To the Editor.
—Greenberg et al1 recently reported that elevated levels of a soluble form of the interleukin 2 receptor (sIl-2r) released by activated lymphoid cells2 are found in the serum samples of patients affected by chronic progressive multiple sclerosis. An increased expression of membrane-bound interleukin 2 receptor on peripheral blood lymphocytes in patients with a relapsing-remitting form of multiple sclerosis has also been described.3 Therefore, we have measured the levels of sIl-2r in the serum samples obtained from 34 patients with clinically defined4 relapsing-remitting multiple sclerosis using an enzyme-linked immunosorbent assay (Tcell Science, Cambridge, Mass). Nine patients (7 females, 2 males; mean age, 29.2 years) were studied during an acute exacerbation, while 25 patients (17 females, 8 males; mean age, 38.9 years) were studied in a period of clinical remission of at least 6 months' duration. None of the patients had taken steroids during the
Capra R, Mattioli F, Marciano' N, et al. Significantly Higher Levels of Soluble Interleukin 2 in Patients With Relapsing-Remitting Multiple Sclerosis Compared With Healthy Subjects. Arch Neurol. 1990;47(3):254. doi:10.1001/archneur.1990.00530030018007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.